Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) is the market leader in long-acting injectable medications for opioid use disorder, operating as a specialty pharmaceutical company focused on delivering evidence-based pharmacotherapies for addiction medicine. The company's website is www.indivior.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Indivior Pharmaceuticals, Inc. does
In the company’s own words
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) is the market leader in long-acting injectable medications for opioid use disorder, operating as a specialty pharmaceutical company focused on delivering evidence-based pharmacotherapies for addiction medicine. The company's website is www.indivior.com.
The company's core business centers on treating opioid use disorder through medication-assisted treatment, combining pharmacological interventions with counseling and behavioral therapies. Indivior's primary marketed products include SUBLOCADE, a monthly buprenorphine extended-release injection that represents the company's largest revenue generator, and SUBOXONE Film, a buprenorphine and naloxone sublingual film. The company also distributes SUBUTEX Tablet in select international markets. SUBLOCADE has treated over 475,000 patients since FDA approval in 2017 and is the only monthly long-acting injectable buprenorphine approved for rapid initiation starting on day one of treatment. SUBOXONE Film faces generic competition in the United States but maintains patent protection in Canada and Europe through 2030.
Geographically, the United States represents approximately 85 percent of net revenues, with additional operations in Canada, Australia, France, and Germany. The company maintains manufacturing capabilities including a Fine Chemical Plant in Hull, United Kingdom that produces buprenorphine active pharmaceutical ingredient, and a manufacturing facility in Raleigh, North Carolina acquired in 2023 to expand production capacity. Indivior relies on contract manufacturing organizations for commercial supply of most products.
The company traces its origins to 1966 when Reckitt & Colman discovered buprenorphine. Following a demerger from Reckitt Benckiser Group in December 2014, Indivior operated as an independent public company. In January 2026, the company completed a domestication to the United States, becoming Indivior Pharmaceuticals, Inc., a Delaware corporation, with its former UK parent company becoming a wholly-owned subsidiary.
Indivior maintains a research and development organization focused on developing new treatments for opioid use disorder and related conditions, supported by approximately 72 employees in chemistry, manufacturing, and controls functions. The company operates under significant regulatory oversight, including compliance obligations from prior settlements with the Department of Justice, Federal Trade Commission, and Health and Human Services Office of Inspector General related to historical marketing practices.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NORTH CHESTERFIELD, VA
- Fiscal year end
- December
- CIK
- 1625297
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Indivior Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Indivior Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Indivior Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Indivior Pharmaceuticals, Inc.’s debt, $90.35M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.63%, maturing 2031 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Indivior Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Indivior Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Indivior Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”